Evaluation of long-term anti-IgE antibody therapy in the patients with wheat allergy

Not Applicable

• Conditions: Wheat allergy

• Registration Number: JPRN-UMIN000019250
• Lead Sponsor: Shimane University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-10-10
• Study Completion: 2018-08-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have hypersensitivity to ingredients of Omalizumab (Novartis Pharma, Japan). 2. Patients who receive immunosuppressive drugs. 3. Patients with decompensated liver cirrhosis. 4. Patients with severe kidney disease; more than 2.0mg/dL of serum creatinine level within 4 weeks prior to the entry. 5. Patients with liver disease, psychiatric disorder, convulsive seizure and seizure disorder, cardiovascular disease, abnormal hemoglobin disease, hemophilia, and autoimmune disease. 6. Pregnant women, breast-feeding women, and women suspected of being pregnant. 7. Patients ineligible for the clinical trial at a physician's discretion.

Study & Design

• Study Type: Interventional
• Study Design: Not specified